Related Experiment Video
Updated: Apr 20, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Novel monoamine oxidase inhibitors: a patent review (2012 - 2014)
Simone Carradori1, Jacobus P Petzer
1Sapienza University of Rome, Department of Drug Chemistry and Technologies , P.le A. Moro 5, 00185, Rome , Italy +39 06 49913149 ; +39 06 49913923 ; simone.carradori@uniroma1.it.
Introduction:
Monoamine oxidase (MAO) inhibitors, despite the initial pharmacological interest, are used in clinic for their antidepressant effect and in the management of Parkinson symptoms, due to the established neuroprotective action. Efficacy and tolerability emerged from large-scale and randomized clinical trials.
Areas Covered:
Thirty-six patents range from April 2012 to September 2014. The number of chemotypes with inhibitory effects on MAO is truly high (40 synthetic compounds, 22 natural products and 6 plant extracts reported and licensed), and the present review is comprehensive of all compounds, which have been patented for their relevance to clinical medicine in this period range (27 patents). Moreover, some of the collected patents deal with new formulations of compounds endowed with MAO inhibitory properties (two patents) and new therapeutic options/drug associations for already known MAO inhibitors (seven patents).
Expert Opinion:
The patents reported in this review showed that the interest in this field is constant and mainly devoted to the study of selective MAO-B inhibitors, used as drugs for the treatment of neurological disorders. The development of novel human MAO inhibitors took advantage of the discovery of new therapeutic targets (cancer, hair loss, muscle dystrophies, cocaine addiction and inflammation), the recognized role of MAOs as molecular biomarkers and their activity in other tissues.
More Related Videos
07:56A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drugs Affecting Neurotransmitter Synthesis
FDA Approved Drugs: Changes to Approved Drugs
Antidepressant Drugs: Overview
Drugs Affecting Neurotransmitter Release or Uptake